With 0.61 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.58 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $22.63 whereas the lowest price it dropped to was $21.595. The 52-week range on KNSA shows that it touched its highest point at $28.15 and its lowest point at $16.56 during that stretch. It currently has a 1-year price target of $35.17. Beta for the stock currently stands at 0.32.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of KNSA was up-trending over the past week, with a rise of 5.19%, but this was up by 14.80% over a month. Three-month performance surged to 4.60% while six-month performance fell -6.41%. The stock gained 8.12% in the past year, while it has gained 13.75% so far this year. A look at the trailing 12-month EPS for KNSA yields -0.61 with Next year EPS estimates of 1.00. For the next quarter, that number is 0.04. This implies an EPS growth rate of 184.80% for this year and 96.46% for next year.
Float and Shares Shorts:
At present, 41.88 million KNSA shares are outstanding with a float of 40.16 million shares on hand for trading. On 2025-02-28, short shares totaled 3.0 million, which was 413.00002000000006 higher than short shares on 1738281600. In addition to Mr. Sanj K. Patel as the firm’s CEO & Chairman of the Board, Mr. Eben Tessari serves as its Senior VP & COO.
Institutional Ownership:
Through their ownership of 0.89809996 of KNSA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, KNSA reported revenue of $122536000.0 and operating income of -$19299000.0. The EBITDA in the recently reported quarter was -$18899000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for KNSA since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With KNSA analysts setting a high price target of 40.0 and a low target of 30.0, the average target price over the next 12 months is 35.16667. Based on these targets, KNSA could surge 77.78% to reach the target high and rise by 33.33% to reach the target low. Reaching the average price target will result in a growth of 56.3% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.30059 being high and -$0.43657 being low. For KNSA, this leads to a yearly average estimate of -$0.39363. Based on analyst estimates, the high estimate for the next quarter is $0.38 and the low estimate is $0.34. The average estimate for the next quarter is thus $0.36.
